<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01786265</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0993</org_study_id>
    <secondary_id>NCI-2018-01856</secondary_id>
    <secondary_id>2012-0993</secondary_id>
    <nct_id>NCT01786265</nct_id>
  </id_info>
  <brief_title>Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer</brief_title>
  <official_title>A Randomized Study of Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone in Patients With Prostate Cancer Who Have PSA Progression After Prostatectomy and/or Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well finite androgen ablation with or without abiraterone&#xD;
      acetate and prednisone work in treating patients with prostate cancer that has come back.&#xD;
      Androgen can cause the growth of prostate cancer cells. Hormone therapy, such as finite&#xD;
      androgen ablation, using leuprolide acetate, goserelin acetate, degarelix, bicalutamide,&#xD;
      flutamide, and nilutamide may fight prostate cancer by lowering the amount of androgen the&#xD;
      body makes. Abiraterone acetate may help to decrease the production of testosterone, and&#xD;
      prednisone may help lower or prevent some side effects. It is not yet known whether giving&#xD;
      acetate, goserelin acetate, degarelix, bicalutamide, flutamide, and nilutamide with or&#xD;
      without abiraterone acetate and prednisone may work better in treating patients with prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate whether finite maximal androgen ablation (8 month), as compared to&#xD;
      luteinizing-hormone-releasing hormone (LHRH) alone, will improve one-year post-treatment&#xD;
      prostate specific antigen (PSA)-free survival by 20%.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine testosterone recovery difference between the two groups. II. Calculate the&#xD;
      PSA-free survival following testosterone recovery. III. To determine in the steroid&#xD;
      biosynthesis metabolome, in the blood and bone marrow of patients at baseline, maximum&#xD;
      response (eight months therapy) and upon PSA progression, evidence of minimal residual cancer&#xD;
      (MD Anderson Cancer Center [MDACC] main campus patients only).&#xD;
&#xD;
      IV. To apply technologies in development able to detect presence of cancer cells (&quot;minimal&#xD;
      residual disease&quot;) at a clinical study milestone (baseline, completion of therapy and upon&#xD;
      PSA progression).&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To explore in archival tissue samples for a candidate predictive signature of outcome&#xD;
      applying technologies for interrogation of protein deoxyribonucleic acid (dna) and&#xD;
      ribonucleic acid (rna) levels of molecular markers / pathways of interest.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM A: Patients receive either leuprolide acetate via injection every month or every 4&#xD;
      months, goserelin acetate via injection every month, or degarelix via injection every month&#xD;
      for 8 months. Patients also receive bicalutamide orally (PO) once daily (QD), flutamide PO&#xD;
      three times daily (TID), or nilutamide PO QD. Patients may crossover to Arm B with disease&#xD;
      progression after 8 months.&#xD;
&#xD;
      ARM B: Patients receive leuprolide acetate, goserelin acetate, degarelix, bicalutamide,&#xD;
      flutamide, or nilutamide as in Arm A. Patients also receive abiraterone acetate PO daily for&#xD;
      8 months and prednisone daily. Patients may crossover to Arm A with disease progression after&#xD;
      8 months.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 and 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 5, 2013</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate-specific antigen (PSA) free survival (PSA &lt; 0.1 ng/ml)</measure>
    <time_frame>At 12 months after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Recurrent Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive either leuprolide acetate via injection every month or every 4 months, goserelin acetate via injection every month, or degarelix via injection every month for 8 months. Patients also receive bicalutamide PO QD, flutamide PO TID, or nilutamide PO QD. Patients may crossover to Arm B with disease progression after 8 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive leuprolide acetate, goserelin acetate, degarelix, bicalutamide, flutamide, or nilutamide as in Arm A. Patients also receive abiraterone acetate PO daily for 8 months and prednisone daily. Patients may crossover to Arm A with disease progression after 8 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>CB7630</other_name>
    <other_name>Yonsa</other_name>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>Casodex</other_name>
    <other_name>Cosudex</other_name>
    <other_name>ICI 176,334</other_name>
    <other_name>ICI 176334</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Given via injection</description>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>FE200486</other_name>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>4''-Nitro-3''-trifluoromethylisobutyranilide</other_name>
    <other_name>Apimid</other_name>
    <other_name>Cebatrol</other_name>
    <other_name>Chimax</other_name>
    <other_name>Cytomid</other_name>
    <other_name>Drogenil</other_name>
    <other_name>Euflex</other_name>
    <other_name>Eulexine</other_name>
    <other_name>Flucinom</other_name>
    <other_name>Flucinome</other_name>
    <other_name>Flugerel</other_name>
    <other_name>Fluken</other_name>
    <other_name>Flulem</other_name>
    <other_name>FLUT</other_name>
    <other_name>Fluta-Gry</other_name>
    <other_name>Flutabene</other_name>
    <other_name>Flutacan</other_name>
    <other_name>Flutamex</other_name>
    <other_name>Flutamin</other_name>
    <other_name>Flutan</other_name>
    <other_name>Flutaplex</other_name>
    <other_name>Fugerel</other_name>
    <other_name>Grisetin</other_name>
    <other_name>Niftolide</other_name>
    <other_name>Oncosal</other_name>
    <other_name>Profamid</other_name>
    <other_name>Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-</other_name>
    <other_name>Prostacur</other_name>
    <other_name>Prostadirex</other_name>
    <other_name>Prostica</other_name>
    <other_name>Prostogenat</other_name>
    <other_name>Sch 13521</other_name>
    <other_name>Tafenil</other_name>
    <other_name>Tecnoflut</other_name>
    <other_name>Testotard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin Acetate</intervention_name>
    <description>Given via injection</description>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>ZDX</other_name>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>Given via injection</description>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>A-43818</other_name>
    <other_name>Abbott 43818</other_name>
    <other_name>Abbott-43818</other_name>
    <other_name>Carcinil</other_name>
    <other_name>Depo-Eligard</other_name>
    <other_name>Eligard</other_name>
    <other_name>Enanton</other_name>
    <other_name>Enantone</other_name>
    <other_name>Enantone-Gyn</other_name>
    <other_name>Ginecrin</other_name>
    <other_name>LEUP</other_name>
    <other_name>Leuplin</other_name>
    <other_name>Leuprorelin Acetate</other_name>
    <other_name>Lucrin</other_name>
    <other_name>Lucrin Depot</other_name>
    <other_name>Lupron</other_name>
    <other_name>Lupron Depot</other_name>
    <other_name>Lupron Depot-3 Month</other_name>
    <other_name>Lupron Depot-4 Month</other_name>
    <other_name>Lupron Depot-Ped</other_name>
    <other_name>Lutrate</other_name>
    <other_name>Procren</other_name>
    <other_name>Procrin</other_name>
    <other_name>Prostap</other_name>
    <other_name>TAP-144</other_name>
    <other_name>Trenantone</other_name>
    <other_name>Uno-Enantone</other_name>
    <other_name>Viadur</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (finite androgen ablation)</arm_group_label>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>Anandron</other_name>
    <other_name>Nilandron</other_name>
    <other_name>RU-23908</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Arm B (finite androgen ablation, abiraterone, prednisone)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have signed an informed consent document indicating that the subjects understand the&#xD;
             purpose of and procedures required for the study and are willing to participate in the&#xD;
             study&#xD;
&#xD;
          -  Written Authorization for Use and Release of Health and Research Study Information has&#xD;
             been obtained&#xD;
&#xD;
          -  Be willing/able to adhere to the prohibitions and restrictions specified in this&#xD;
             protocol&#xD;
&#xD;
          -  Life expectancy &gt;= 12 months&#xD;
&#xD;
          -  ECOG performance status (PS) =&lt; 2&#xD;
&#xD;
          -  Histologically documented diagnosis of adenocarcinoma of the prostate (PCa) with no&#xD;
             histologic variants&#xD;
&#xD;
          -  Prostate cancer recurrence after definitive local therapy (radical prostatectomy&#xD;
             and/or radiation therapy) as evidenced by rising serum PSA, without evidence of&#xD;
             metastases by bone scan or computed tomography (CT) scan&#xD;
&#xD;
               -  After radiation: A rising PSA taken to indicate recurrent prostate cancer in&#xD;
                  patients with previous definitive external beam radiotherapy will be defined as&#xD;
                  PSA of 1.0&#xD;
&#xD;
               -  After Radical Prostatectomy: A rising PSA taken to indicate recurrent prostate&#xD;
                  cancer in patients with previous radical prostatectomy will be defined by the&#xD;
                  criteria of the American Urological Association as any PSA measurement of 0.2,&#xD;
                  with a subsequent measurement &gt; 0.2 ng/mL&#xD;
&#xD;
          -  Patients who have received androgen ablative therapy for less than 8 weeks immediately&#xD;
             prior to initiation of study drug are eligible provided they had only PSA evidence of&#xD;
             progression (as defined above) with no visible metastases by CT-scan and bone scan&#xD;
             (within 6 weeks) prior to starting androgen ablation&#xD;
&#xD;
          -  White blood cell (WBC) &gt;= 3.5 x 10^9/L&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelets &gt;= 100 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin (Hb) &gt;= 9.0 g/dL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 1.5 x the upper&#xD;
             limit of normal&#xD;
&#xD;
          -  Serum potassium of &gt;= 3.5 mEq/L&#xD;
&#xD;
          -  Serum albumin of &gt;= 3.0 g/dL&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Patients must have recovered from prior treatment regimens, e.g. surgery, radiation&#xD;
&#xD;
          -  A patient who is sexually active and their partner must agree and use two reliable&#xD;
             barrier forms of contraception (for example, condoms and diaphragm), from first day of&#xD;
             study drug administration until for 1 week after last dose of abiraterone acetate,&#xD;
             unless partner is post-menopausal&#xD;
&#xD;
          -  Able to swallow the study drug whole as a tablet&#xD;
&#xD;
          -  Willing to take abiraterone acetate on an empty stomach; no food should be consumed at&#xD;
             least two hours before and for at least one hour after the dose of abiraterone acetate&#xD;
             is taken&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received prior hormonal therapy are excluded from the trial, except&#xD;
             for: patients who have received up to 6 months of hormonal therapy as neoadjuvant&#xD;
             therapy before radical prostatectomy or while on radiation therapy, as long as more&#xD;
             than 1 year has elapsed between discontinuation of the neoadjuvant hormonal therapy&#xD;
             and initiation of hormonal treatment for relapsing disease&#xD;
&#xD;
          -  Any known metastases&#xD;
&#xD;
          -  Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (&gt;= 450 msec)&#xD;
&#xD;
          -  Clinically significant heart disease as evidenced by myocardial infarction, or&#xD;
             arterial thrombotic events in the past 6 months, severe or unstable angina, or New&#xD;
             York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction&#xD;
             measurement of &lt; 50% at baseline&#xD;
&#xD;
          -  Significant co-morbidity that could affect the safety or evaluability of participants&#xD;
             as assessed by the treating physician and or principal investigator&#xD;
&#xD;
          -  Prior therapy with strontium-89, samarium, rhenium-186 etidronate, chemotherapy or&#xD;
             androgen biosynthesis inhibitors for prostate cancer is not allowed. Previous&#xD;
             immunologic, homeopathic, natural, or alternative medicine therapies are acceptable&#xD;
             provided treatment ended greater than 28 days prior to initiation of study drug&#xD;
&#xD;
          -  Patients who, in the opinion of the investigator, are unable to comply with the&#xD;
             requirements of the study protocol are not eligible&#xD;
&#xD;
          -  Active infection or other medical condition that would make prednisone/prednisolone&#xD;
             (corticosteroid) use contraindicated&#xD;
&#xD;
          -  Active or symptomatic viral hepatitis&#xD;
&#xD;
          -  History of pituitary or adrenal dysfunction&#xD;
&#xD;
          -  Administration of an investigational therapeutic drug within 30 days of cycle 1 day 1&#xD;
&#xD;
          -  Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or&#xD;
             prednisone or their excipients&#xD;
&#xD;
          -  Have a history of gastrointestinal disorders (medical disorders or extensive surgery)&#xD;
             that may interfere with the absorption of the study agents&#xD;
&#xD;
          -  Have a pre-existing condition that warrants long-term corticosteroid use in excess of&#xD;
             study dose&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Logothetis</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2013</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Flutamide</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Nilutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

